home / stock / lgvn / lgvn articles

LGVN Articles, Longeveron Inc. - From 01/03/24

Stock Information
Company Name: Longeveron Inc.
Stock Symbol: LGVN
Market: NASDAQ
Website: longeveron.com
Menu
LGVN LGVN Quote LGVN Short LGVN News LGVN Articles LGVN Message Board
Get LGVN Alerts

News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying | Benzinga

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern a...
Nasdaq Gains 100 Points; CarMax Earnings Top Views | Benzinga

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to ...

Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. KMX reported a t...

Crude Oil Moves Lower; Micron Issues Strong Forecast | Benzinga

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37...
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Benzinga

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company devel...

Why Longeveron (LGVN) Shares Are Falling Sharply | Benzinga

Longeveron Inc (NASDAQ: LGVN) shares are trading lower by 22.8% to $1.25 Thursday morning after the company has finalized an agreement for a r...

Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Benzinga

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company devel...
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™ | Benzinga

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell...

Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association | Benzinga

Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct...

Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 | Benzinga

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnolo...
Previous 10 Next 10